Status:
RECRUITING
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Cytomegalovirus Infections
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assesse...
Detailed Description
This study aim to evaluate the performances of this new assay to predict the risk of CytoMegaloVirus (CMV) reactivation in the colon of UC patients. A new algorithm for the care of Ulcerative Colitis ...
Eligibility Criteria
Inclusion
- Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)
- Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score \> 5 and an endoscopic subscore ≥ 2
- Social security affiliation
- Signed informed consent
Exclusion
- Wardship patient and curatorial patient
- Patient unable to understand or sign the protocol
- Colectomy total or partial
Key Trial Info
Start Date :
July 17 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT04030676
Start Date
July 17 2019
End Date
April 1 2026
Last Update
April 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
HCL-Hôpital Lyon Sud
Lyon, France
2
Chu Saint-Etienne
Saint-Etienne, France